EUCTR2008-003879-49-GB进行中（未招募）不适用
A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and the effect of different doses of Oralgen House Dust Mite in patients with house dust mite induced allergic rhinoconjunctivitis
Artu Biologicals Europe B.V.0 个研究点开始时间: 2008年6月27日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female between 18 and 60 years of age (inclusive).
- •2. House-dust mite induced allergy with moderate to severe rhinitis symptoms
- •for at least one year.
- •3. RRTSS score of greater than or equal to 10 out of a maximal score of 18.
- •4. Sensitized to D pter and D far as indicated by a specific RAST of at least
- •class 2 and a positive skin prick test (i.e. wheal diameter equal to or more
- •than 3 mm larger than the negative diluent control).
- •5. Positive D pter nasal provocation test at screening.
- •6. Patients who have been informed of the nature and aims of the study and
- •have given their written consent to participate in this study.
- •7. Patients who are willing to comply with the protocol and understand the
- •information given and the text of the consent form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Other clinically relevant allergies (perennial or seasonal) that could potentially
- •interfere with the patient's study treatment schedule or assessments. Patients
- •with allergic rhinoconjunctivitis due to allergens to which the patient is not
- •exposed to during the study are allowed into the study.
- •2. Patients who lack general good health as determined by past medical history,
- •physical examination, 12-lead ECG and safety laboratory tests.
- •3. Patients with a past or current disease, which as judged by the investigator,
- •may affect the patient’s participation in or the outcome of this study.
- •4. Abnormal spirometry: Forced Expiratory Volume in 1 second (FEV1) at least
- •80% of the predicted value at screening.
- •5. A lower respiratory tract infection within 4 weeks or an upper respiratory tract
- •infection within 2 weeks of the screening visit.
- •6. Asthma requiring treatment other than beta-2 inhaled agonists. Patients with
- •intermittent asthma not necessitating inhaled or systemic corticoid treatment
- •may be included.
- •7. Use of oral steroids within 12 weeks before the screening visit.
- •8. Treatment with beta-blockers or continuous systemic corticosteroid therapy.
- •9. Previous immunotherapy treatment with house dust mite (HDM) or other
- •allergen extracts within the last five years.
- •10. Participation in any other clinical study within the previous 90 days.
- •11. Positive urine pregnancy test.
- •12. Pregnancy, breast-feeding / lactation or sexually active women of
- •childbearing potential who are not using a medically accepted contraceptive
- •13. Patients with any nasal or ocular condition that could confound the effect
- •assessments (for example nasal polyposis).
- •14. The intention to subject the patient to surgery of the nasal cavity during the
- •current study.
- •15. The usual contraindications of immunotherapy such as the following:
- •Malignancies and oral cavity lesions recurring at least twice per year;
- •History of status asthmaticus and anaphylactic shock;
- •Aggressively developing asthmatic symptoms;
- •Serious chronic inflammations, chronic disorders associated with fever,
- •particularly of the bronchial tubes;
- •Irreversible, secondary changes in reactive organs (emphysema,
- •bronchiectasis);
- •Auto-immune diseases and immunodeficiency;
- •Concurrent therapy involving immunosuppressives;
- •Systemic and collagen diseases;
- •Tuberculosis;
- •Serious psychological disorders;
- •Documented hypersensitivity to glycerol;
- •Use of beta-blockers;
- •16. Known infection with hepatitis B, hepatitis C or human immunodeficiency
- •17. Patients who received blood in the previous 90 days.
- •18. Patients with a history of drug or alcohol abuse within the past 5 years.
- •19. Patients at risk of non-compliance.
- •20. Family members of investigators, co-investigators, and all the study
- •collaborators should not be enrolled in the study.
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and tolerability of Oralgen Birch Pollen immunotherapy in patients with allergic rhinoconjunctivitisAllergic rhinoconjunctivitisMedDRA version: 9.1Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisEUCTR2008-003861-17-SEArtu Biologicals Europe B.V.
进行中（未招募）
不适用
Fulvestrant +/- vandetanib in advanced aromatase inhibitor resistant breast cancer.Metastatic breast cancer that has become resistant to aromatase inhibitor therapyEUCTR2014-001208-23-GBVelindre NHS Trust
进行中（未招募）
1 期
Pirfenidone in heart failure with preserved ejection fractioHeart failure with preserved ejection fraction (HFpEF)MedDRA version: 19.0Level: LLTClassification code 10069211Term: Diastolic heart failureSystem Organ Class: 100000004849MedDRA version: 19.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849EUCTR2016-002647-42-GBniversity Hospital of South Manchester
已完成
不适用
Phase I study to assess the pharmacokinetics and pharmacodynamics of macitentan in Korean healthy male subjectsDiseases of the circulatory systemKCT0000326Actelion Pharmaceuticals Korea30
招募中
1 期
A placebo-controlled study to evaluate the safety, tolerability, biochemical and physiologic effects of two infusions of escalating doses of TPM502 in adults diagnosed with celiac diseaseEUCTR2022-001656-41-FITopas Therapeutics GmbH42